Overview

Safety, Toleration and Efficacy of Single Inhaled Doses of PF-00610355 in Chronic Obstructive Pulmonary (COPD) Patients.

Status:
Completed
Trial end date:
2009-03-01
Target enrollment:
Participant gender:
Summary
This study will look at the pharmacokinetics, safety, toleration and efficacy of PF-00610355 in the chronic obstructive pulmonary disease (COPD) population. The doses in this study are intended to explore the anticipated clinical dose range.
Phase:
Phase 2
Details
Lead Sponsor:
Pfizer